Kirin Group

Kirin Holdings is a major Japanese conglomerate that has successfully diversified from its brewery roots into a global leader in pharmaceuticals and health sciences. Through its core subsidiary, Kyowa Kirin, the group focuses on the discovery and commercialization of innovative biologics and small molecules, particularly in the fields of oncology, nephrology, and rare diseases. The company is renowned for its proprietary POTELLIGENT technology, which enhances the efficacy of therapeutic antibodies. Recently, Kirin has expanded its 'Health Science' domain through the acquisition of Blackmores, aiming to bridge the gap between food and medicine with functional supplements. The group leverages over a century of expertise in fermentation and biotechnology to drive its R&D pipeline.